Kopechek Jonathan A, Abruzzo Todd M, Wang Boyu, Chrzanowski Stephen M, Smith Denise A B, Kee Patrick H, Huang Shaoling, Collier Joel H, McPherson David D, Holland Christy K
Department of Biomedical Engineering, University of Cincinnati, Cincinnati, OH 45267-0586 USA.
J Ultrasound Med. 2008 Nov;27(11):1597-606. doi: 10.7863/jum.2008.27.11.1597.
To achieve ultrasound-controlled drug delivery using echogenic liposomes (ELIPs), we assessed ultrasound-triggered release of hydrophilic and lipophilic agents in vitro using color Doppler ultrasound delivered with a clinical 6-MHz compact linear array transducer.
Calcein, a hydrophilic agent, and papaverine, a lipophilic agent, were each separately loaded into ELIPs. Calcein-loaded ELIP (C-ELIP) and papaverine-loaded ELIP (P-ELIP) solutions were circulated in a flow model and treated with 6-MHz color Doppler ultrasound or Triton X-100. Treatment with Triton X-100 was used to release the encapsulated calcein or papaverine content completely. The free calcein concentration in the solution was measured directly by spectrofluorimetry. The free papaverine in the solution was separated from liposome-bound papaverine by spin column filtration, and the resulting papaverine concentration was measured directly by absorbance spectrophotometry. Dynamic changes in echogenicity were assessed with low-output B-mode ultrasound (mechanical index, 0.04) as mean digital intensity.
Color Doppler ultrasound caused calcein release from C-ELIPs compared with flow alone (P < .05) but did not induce papaverine release from P-ELIPs compared with flow alone (P > .05). Triton X-100 completely released liposome-associated calcein and papaverine. Initial echogenicity was higher for C-ELIPs than P-ELIPs. Color Doppler ultrasound and Triton X-100 treatments reduced echogenicity for both C-ELIPs and P-ELIPs (P < .05).
The differential efficiency of ultrasound-mediated pharmaceutical release from ELIPs for water- and lipid-soluble compounds suggests that water-soluble drugs are better candidates for the design and development of ELIP-based ultrasound-controlled drug delivery systems.
为了利用超声造影脂质体(ELIPs)实现超声控制药物递送,我们使用临床6兆赫紧凑型线性阵列换能器发出的彩色多普勒超声,在体外评估了亲水性和亲脂性药物的超声触发释放。
将亲水性药物钙黄绿素和亲脂性药物罂粟碱分别载入ELIPs。将载有钙黄绿素的ELIP(C-ELIP)溶液和载有罂粟碱的ELIP(P-ELIP)溶液在流动模型中循环,并使用6兆赫彩色多普勒超声或 Triton X-100进行处理。用 Triton X-100处理以完全释放包封的钙黄绿素或罂粟碱含量。通过荧光分光光度法直接测量溶液中游离钙黄绿素的浓度。通过旋转柱过滤将溶液中的游离罂粟碱与脂质体结合的罂粟碱分离,并用吸光分光光度法直接测量所得罂粟碱浓度。用低输出B型超声(机械指数,0.04)作为平均数字强度评估回声性的动态变化。
与单纯流动相比,彩色多普勒超声导致钙黄绿素从C-ELIPs中释放(P <.05),但与单纯流动相比,未诱导罂粟碱从P-ELIPs中释放(P>.05)。Triton X-100完全释放了与脂质体相关的钙黄绿素和罂粟碱。C-ELIPs的初始回声性高于P-ELIPs。彩色多普勒超声和 Triton X-100处理均降低了C-ELIPs和P-ELIPs的回声性(P <.05)。
超声介导的ELIPs对水溶性和脂溶性化合物的药物释放效率不同,这表明水溶性药物更适合用于基于ELIPs的超声控制药物递送系统的设计和开发。